Correction to: British Journal of Cancer (2019) 120, 612–620; https://doi.org/10.1038/s41416-019-0389-6; published online 22 February 2019.
The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following:
M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.
The authors apologise for any convenience this may have caused.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Serrano, C., Mariño-Enríquez, A., Tao, D.L. et al. Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer 121, 281 (2019). https://doi.org/10.1038/s41416-019-0487-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-019-0487-5
- Springer Nature Limited